Ghost Tree Capital’s Krystal Biotech KRYS Stock Holding History

Ghost Tree Capital’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,500	Closed	-$1.56M	–	66
2024 Q2	$1.56M	Sell	8,500 -5,500	-39%	-$923K	0.49%	47
2024 Q1	$2.49M	Sell	14,000 -36,000	-72%	-$5M	0.69%	49
2023 Q4	$6.2M	Sell	50,000 -30,000	-38%	-$3.33M	2.03%	12
2023 Q3	$9.28M	Buy	80,000 +60,000	+300%	+$7.32M	3.05%	6
2023 Q2	$2.35M	Buy	+20,000	New	+$2.04M	0.78%	34

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's KRYS Position: Q3 2024 in Review

Ghost Tree Capital sold out of Krystal Biotech (KRYS) in Q3 2024, closing a stake of 8,500 shares — an estimated $1.56M sold.

Ghost Tree Capital first reported a position in KRYS in Q2 2023 and held it in 5 quarters. The position peaked at $9.28M in Q3 2023. 283 funds tracked by Wall St. Rank hold KRYS as of Q3 2024.

Ghost Tree Capital reported no remaining Krystal Biotech position as of Q3 2024 after selling out during the quarter.
Ghost Tree Capital sold 8,500 Krystal Biotech shares in Q3 2024, an estimated $1.56M.
Ghost Tree Capital first reported a position in Krystal Biotech in Q2 2023 and held it in 5 quarters.
Ghost Tree Capital's Krystal Biotech position peaked at $9.28M in Q3 2023.
283 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.